Xponance Inc. Has $22.28 Million Holdings in Pfizer Inc. $PFE

Xponance Inc. lowered its position in Pfizer Inc. (NYSE:PFE) by 2.8% during the third quarter, according to its most recent filing with the SEC. The firm owned 874,577 shares of the biopharmaceutical company’s stock after selling 25,024 shares during the period. Xponance Inc.’s holdings in Pfizer were worth $22,284,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of PFE. Grey Fox Wealth Advisors LLC bought a new position in shares of Pfizer in the 3rd quarter worth about $29,000. Howard Hughes Medical Institute bought a new position in shares of Pfizer during the 2nd quarter worth approximately $30,000. True Wealth Design LLC grew its position in shares of Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 974 shares during the period. Darwin Wealth Management LLC bought a new stake in shares of Pfizer in the 2nd quarter valued at $32,000. Finally, Evelyn Partners Asset Management Ltd acquired a new position in shares of Pfizer during the 2nd quarter valued at $33,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on PFE shares. Citigroup started coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price target for the company. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. HSBC reiterated a “buy” rating and issued a $29.00 target price on shares of Pfizer in a report on Wednesday, December 10th. Morgan Stanley lowered their price objective on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a report on Friday, December 12th. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $27.70.

Pfizer Price Performance

Shares of NYSE PFE opened at $27.11 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $154.14 billion, a PE ratio of 19.93 and a beta of 0.47. The stock’s 50 day moving average price is $26.08 and its 200-day moving average price is $25.39. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.94.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.63 earnings per share. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.3%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is currently 126.47%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.